Captopril in congestive heart failure.

Liebau, G.; Riegger, A. J. G.; Schanzenbächer, P.; Steilner, H.; Oehrlein, S.

doi:10.1111/j.1365-2125.1982.tb02077.x

Cited by 10 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Angiotensin Converting Enzyme inhibitors (ACEis) and Angiotensin Receptor Blockers (ARBs) are classes of drugs that are vasodilators. Captopril, an ACEi, was first tested in heart failure patients in the late 1970s [190] . These classes of drugs were shown to have multiple favorable pharmacologic effects in diabetic nephropathy [191] – [193] , post-MI with left ventricular dysfunction [194] , and for the prevention of AF [195] – [200] .…”

Section: Rhythm Controlmentioning

confidence: 99%

Atrial fibrillation

Thomas,

Li-Qun,

Win

2014

J Biomed Res

View full text Add to dashboard Cite

Atrial fibrillation is the most common arrhythmia affecting patients today. Disease prevalence is increasing at an alarming rate worldwide, and is associated with often catastrophic and costly consequences, including heart failure, syncope, dementia, and stroke. Therapies including anticoagulants, anti-arrhythmic medications, devices, and non-pharmacologic procedures in the last 30 years have improved patients' functionality with the disease. Nonetheless, it remains imperative that further research into AF epidemiology, genetics, detection, and treatments continues to push forward rapidly as the worldwide population ages dramatically over the next 20 years.

show abstract

Section: Rhythm Controlmentioning

confidence: 99%

Atrial fibrillation

Thomas,

Li-Qun,

Win

2014

J Biomed Res

View full text Add to dashboard Cite

show abstract

“…With a single oral dose its maximum hemodynamic effect is observed after 45-90 minutes. 1 The drug is also freely water soluble, has an elimination half-life of 1.7 hours, and is stable at pH 1.2. As the pH increases, CAP becomes unstable and undergoes degradation.…”

Section: Introductionmentioning

confidence: 99%

New formulation of an old drug in hypertension treatment: the sustained release of captopril from cyclodextrin nanoparticles

Azevedo¹,

Tasic²,

Fattori³

et al. 2011

IJN

View full text Add to dashboard Cite

Captopril (CAP) was the first angiotensin I-converting enzyme (ACE) inhibitor to be developed and is widely used in hypertension treatment. On the other hand, cyclodextrins (CDs) are cyclic oligosaccharides whose cone-shaped cavity allows formation of noncovalent inclusion complexes with appropriately sized guest molecules, thus modifying guest physical, chemical, and biological properties. Herein, the physicochemical characterization and in vivo ACE inhibition evaluation of seven CAP/CD complexes are reported. The inclusion complexes were prepared by spray-drying, freeze-drying, kneading, or lyophilization methods and characterized by nuclear magnetic resonance, Fourier-transformed infrared spectroscopy, X-ray diffraction, differential scanning calorimetry, and scanning electron microscopy techniques. In vivo assays compared CAP and CAP/CD complex administration (0.5 mg kg −1 or 0.09 mg kg −1 , n = 4–7) to evaluate the ACE inhibition by continuous infusion of angiotensin I (30 ng 50 μL −1 min −1 ) in conscious Wistar rats. The physicochemical analysis demonstrated complete amorphization and complexation between CAP and CDs, indicating the substitution of water molecules inside the CD cavity with CAP. During the infusion of angiotensin I, the administration of all CAP/CD complexes induced a reduction in mean arterial pressure similar to that observed upon CAP administration. The nanoparticles obtained by the kneading method (CAP/α-CD:KM) showed a potent and long-lasting inhibitory activity (∼22 hours) on the angiotensin I pressor effect. The results suggest that the inclusion complex of CAP and α-CD can function as a novel antihypertensive formulation that may improve therapeutic use of CAP by reducing its oral dose administration to once per day, thus providing better quality of life for almost 25% of the world’s population who suffer from hypertension.

show abstract

Converting Enzyme Inhibition: Therapy for Chronic Heart Failure

Bussmann

1986

Acute and Chronic Heart Failure

View full text Add to dashboard Cite

Captopril in congestive heart failure.

Cited by 10 publications

References 7 publications

Atrial fibrillation

Atrial fibrillation

New formulation of an old drug in hypertension treatment: the sustained release of captopril from cyclodextrin nanoparticles

Converting Enzyme Inhibition: Therapy for Chronic Heart Failure

Contact Info

Product

Resources

About